Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Journal of Medicinal Chemistry|June 29, 2026
Dual Targeting of Nucleotidase-Dependent and -Independent Functions via PROTAC-Mediated CD73 DegradationPing Xie, Jie Fan, Longzhen Song, et al.
Cancer Research|December 16, 2014
Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanismSiqi Chen, Long Wang, Jie Fan, et al.
The Journal of Investigative Dermatology|September 13, 2021
IL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic WoundsRuchi Roy, Janet Zayas, Mohamed F Mohamed, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 15, 2021
Therapeutic evaluation of immunomodulators in reducing surgical wound infectionFoyez Mahmud, Ruchi Roy, Mohamed F Mohamed, et al.
International Journal of Radiation Oncology, Biology, Physics|July 24, 2012
Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphomaTarita O Thomas, Priya Agrawal, Joan Guitart, et al.
Nature Communications|March 12, 2022
CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoTMohamed F Mohamed, Kajal Gupta, Josef W Goldufsky, et al.
European Urology|December 26, 2017
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8<sup>+</sup> T-cells Derived from Patients with Metastatic Castrate-resistant DiseaseQiang Zhang, Brian T Helfand, Benedito A Carneiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2011
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteinsChristiane Querfeld, Steven T Rosen, Joan Guitart, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 29, 2010
A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC)Elizabeth Atchison, John Eklund, Brenda Martone, et al.
Clinical Lymphoma|April 24, 2002
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)Madeleine Duvic, Timothy M Kuzel, Elise A Olsen, et al.
Pageof 12